This study is conducted in Asia. The aim of this observational study is to evaluate safety, efficacy and convenience in using NovoMix® 30 FlexPen® in type 2 diabetes under normal clinical practice conditions.
Study Type
OBSERVATIONAL
Enrollment
1,584
No intervention is done. For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
Novo Nordisk Investigational Site
Jakarta, Indonesia
Change in HbA1c
Time frame: after 12 weeks of therapy
Change in post-prandial glucose (PPG)
Time frame: after 12 weeks of therapy
Change in fasting plasma glucose (FPG)
Time frame: after 12 weeks of therapy
Change in prandial glucose increment (PGI)
Time frame: after 12 weeks of therapy
Incidence of hypoglycaemia and other adverse drug reaction
Time frame: after 12 weeks of therapy
Patient and doctor's convenience
Time frame: after 12 weeks of therapy
Response of different patient profiles to NovoMix 30 therapy and patient profiles considered eligible for insulin treatment in physicians' routine clinical practice
Time frame: For the duration of the study
Patient satisfaction on devices
Time frame: after 12 weeks of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.